Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

Alfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah Thomas, Steven Kornblau, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

142 Scopus citations

Fingerprint

Dive into the research topics of 'Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds